Medical Care
Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Research Report 2025
- Jul 08, 25
- ID: 347794
- Pages: 78
- Figures: 74
- Views: 31
The global market for Gastroenteropancreatic Neuroendocrine Tumor Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroenteropancreatic Neuroendocrine Tumor Therapeutics.
The Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis, Inc.
Tarveda Therapeutics
Segment by Type
Chemotherapy
Peptide-Receptor Radionuclide Therapy
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroenteropancreatic Neuroendocrine Tumor Therapeutics.
The Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Fresenius Kabi
Teva Pharmaceuticals
Sun Pharma
Hutchison China MediTech Limited
Exelixis, Inc.
Tarveda Therapeutics
Segment by Type
Chemotherapy
Peptide-Receptor Radionuclide Therapy
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Peptide-Receptor Radionuclide Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2020-2031)
2.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Region
2.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Dynamics
2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Trends
2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue
3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue
3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio
3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024
3.5 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Head office and Area Served
3.6 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application
3.7 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type
4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031)
5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application
5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.2.5 Pfizer Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Details
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.3.5 Fresenius Kabi Recent Development
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Details
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.4.5 Teva Pharmaceuticals Recent Development
11.5 Sun Pharma
11.5.1 Sun Pharma Company Details
11.5.2 Sun Pharma Business Overview
11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.5.5 Sun Pharma Recent Development
11.6 Hutchison China MediTech Limited
11.6.1 Hutchison China MediTech Limited Company Details
11.6.2 Hutchison China MediTech Limited Business Overview
11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.6.5 Hutchison China MediTech Limited Recent Development
11.7 Exelixis, Inc.
11.7.1 Exelixis, Inc. Company Details
11.7.2 Exelixis, Inc. Business Overview
11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.7.5 Exelixis, Inc. Recent Development
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.8.5 Tarveda Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Peptide-Receptor Radionuclide Therapy
1.2.4 Others
1.3 Market by Application
1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2020-2031)
2.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Region
2.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Dynamics
2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Trends
2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue
3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue
3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio
3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024
3.5 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Head office and Area Served
3.6 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application
3.7 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type
4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031)
5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application
5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.1.5 Novartis Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.2.5 Pfizer Recent Development
11.3 Fresenius Kabi
11.3.1 Fresenius Kabi Company Details
11.3.2 Fresenius Kabi Business Overview
11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.3.5 Fresenius Kabi Recent Development
11.4 Teva Pharmaceuticals
11.4.1 Teva Pharmaceuticals Company Details
11.4.2 Teva Pharmaceuticals Business Overview
11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.4.5 Teva Pharmaceuticals Recent Development
11.5 Sun Pharma
11.5.1 Sun Pharma Company Details
11.5.2 Sun Pharma Business Overview
11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.5.5 Sun Pharma Recent Development
11.6 Hutchison China MediTech Limited
11.6.1 Hutchison China MediTech Limited Company Details
11.6.2 Hutchison China MediTech Limited Business Overview
11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.6.5 Hutchison China MediTech Limited Recent Development
11.7 Exelixis, Inc.
11.7.1 Exelixis, Inc. Company Details
11.7.2 Exelixis, Inc. Business Overview
11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.7.5 Exelixis, Inc. Recent Development
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction
11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
11.8.5 Tarveda Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Peptide-Receptor Radionuclide Therapy
Table 4. Key Players of Others
Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2025)
Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2026-2031)
Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)
Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application
Table 22. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Novartis Company Details
Table 48. Novartis Business Overview
Table 49. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 50. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Novartis Recent Development
Table 52. Pfizer Company Details
Table 53. Pfizer Business Overview
Table 54. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 55. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Fresenius Kabi Company Details
Table 58. Fresenius Kabi Business Overview
Table 59. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 60. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Fresenius Kabi Recent Development
Table 62. Teva Pharmaceuticals Company Details
Table 63. Teva Pharmaceuticals Business Overview
Table 64. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 65. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Teva Pharmaceuticals Recent Development
Table 67. Sun Pharma Company Details
Table 68. Sun Pharma Business Overview
Table 69. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 70. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Sun Pharma Recent Development
Table 72. Hutchison China MediTech Limited Company Details
Table 73. Hutchison China MediTech Limited Business Overview
Table 74. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 75. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Hutchison China MediTech Limited Recent Development
Table 77. Exelixis, Inc. Company Details
Table 78. Exelixis, Inc. Business Overview
Table 79. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 80. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Exelixis, Inc. Recent Development
Table 82. Tarveda Therapeutics Company Details
Table 83. Tarveda Therapeutics Business Overview
Table 84. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 85. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 86. Tarveda Therapeutics Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
Table 90. Authors List of This Report
List of Figures
Figure 1. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Picture
Figure 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Chemotherapy Features
Figure 5. Peptide-Receptor Radionuclide Therapy Features
Figure 6. Others Features
Figure 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered
Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2024
Figure 18. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024
Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2031)
Figure 34. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 50. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 51. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 53. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 54. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 55. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 56. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Peptide-Receptor Radionuclide Therapy
Table 4. Key Players of Others
Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2025)
Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2026-2031)
Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends
Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers
Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges
Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints
Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)
Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application
Table 22. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Novartis Company Details
Table 48. Novartis Business Overview
Table 49. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 50. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 51. Novartis Recent Development
Table 52. Pfizer Company Details
Table 53. Pfizer Business Overview
Table 54. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 55. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Pfizer Recent Development
Table 57. Fresenius Kabi Company Details
Table 58. Fresenius Kabi Business Overview
Table 59. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 60. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Fresenius Kabi Recent Development
Table 62. Teva Pharmaceuticals Company Details
Table 63. Teva Pharmaceuticals Business Overview
Table 64. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 65. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Teva Pharmaceuticals Recent Development
Table 67. Sun Pharma Company Details
Table 68. Sun Pharma Business Overview
Table 69. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 70. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Sun Pharma Recent Development
Table 72. Hutchison China MediTech Limited Company Details
Table 73. Hutchison China MediTech Limited Business Overview
Table 74. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 75. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Hutchison China MediTech Limited Recent Development
Table 77. Exelixis, Inc. Company Details
Table 78. Exelixis, Inc. Business Overview
Table 79. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 80. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Exelixis, Inc. Recent Development
Table 82. Tarveda Therapeutics Company Details
Table 83. Tarveda Therapeutics Business Overview
Table 84. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product
Table 85. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)
Table 86. Tarveda Therapeutics Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources
Table 90. Authors List of This Report
List of Figures
Figure 1. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Picture
Figure 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Chemotherapy Features
Figure 5. Peptide-Receptor Radionuclide Therapy Features
Figure 6. Others Features
Figure 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered
Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2024
Figure 18. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024
Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2031)
Figure 34. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 50. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 51. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 53. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 54. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 55. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 56. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232